In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole.

Drugs Exp Clin Res. 1996;22(6):301-7. Unique Identifier : AIDSLINE MED/97187303
Mallie M; Bastide JM; Immunology-Parasitology Laboratory, Faculty of Pharmacy, Montpellier,; France.

Abstract: Opportunistic fungal infections are an increasingly important cause of morbidity and mortality particularly due to Candida species (1). There is also an increase of candidosis especially ascribed to acquired or induced immunodeficiency syndromes or in the event of long-term antibiotic, immuno-suppressor or cytotoxic therapies. Consequently there has been an increase in the use of systemic antifungal agents responsible for the emergence of new opportunistic fungi (2) and resistant species (3, 4). Oropharyngeal candidiasis caused by various species of Candida is one of the most common opportunistic infections in AIDS. In recent years there has been an increasing number of yeast isolates resistant to fluconazole (4, 5) or to amphotericin B 6). The aim of the present study was to examine the susceptibility in vitro of itraconazole, a newly introduced antifungal agent in the local or systemic therapy of oropharyngeal candidiosis, vs well-known agents such as amphotericin B and fluconazole, against various Candida clinical isolates. The present results, in agreement with other studies, show strong in vitro activity of itraconazole against Candida spp. and particularly against less susceptible species C. glabrata, C. tropicalis or C. krusei.
Keywords: *Amphotericin B/PHARMACOLOGY *Antifungal Agents/PHARMACOLOGY *Candida/DRUG EFFECTS *Fluconazole/PHARMACOLOGY *Itraconazole/PHARMACOLOGYKWDamphotericinb/pharmacologyKWDantifungalagents/pharmacologyKWDcandida/drugeffectsKWDfluconazole/pharmacologyKWDitraconazole/pharmacology
970730
M9772100

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .